AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
In a study analyzing the clinical effects of citalopram serum levels in patients with major depressive disorder (MDD), a significant number of patients who had serum concentrations of <50 ng/ mL showed less than favorable treatment outcomes, even at therapeutic doses.
Citalopram and other selective serotonin reuptake inhibitors (SSRIs) are firstline treatment for patients with MDD. Despite widespread availability and evidence-based treatment guidelines recommending SSRIs for MDD, a considerable number of SSRI-treated patients are partial or nonresponders, and may need a longer period of treatment to achieve remission.
Citalopram is widely used, since it has a lower risk of pharmacokinetic interactions compared with other SSRIs such as fluoxetine, fluvoxamine, or paroxetine. …